Valsartan Promoting Atherosclerotic Plaque Stabilization by Upregulating Renalase: A Potential-Related Gene of Atherosclerosis.

Abstract:

BACKGROUND:Renalase is a protein that can regulate sympathetic nerve activity by metabolizing catecholamines, while redundant catecholamines are thought to contribute to atherosclerosis (As). Catecholamine release can be facilitated by angiotensin (Ang) II by binding to Ang II type 1 (AT1) receptors. Valsartan, a special AT1 antagonist, can dilate blood vessels and reduce blood pressure, but it remained unclear whether valsartan can promote the stability of atherosclerotic plaque by affecting renalase. OBJECTIVE:This study examined the tissue distribution of renalase in ApoE(-/-) mice fed with a high-fat diet and the effect of valsartan on expression of renalase. METHODS:ApoE(-/-) mice were fed with a high-fat diet for 13 or 26 weeks. As a control, 10 C57BL mice were fed with a standard chow diet. After 13 weeks on the high-fat diet, the ApoE(-/-) mice were randomized (10 mice/group) and treated with valsartan, simvastatin, or distilled water (control group) for an additional 13 weeks accompanied by a high-fat diet. RESULTS:Knockout of ApoE caused a dramatic increase in expression of renalase in mice adipose tissue. With the disturbance of lipid metabolism induced by a high-fat diet, renalase expression decreased in the liver. Renalase can be expressed in smooth muscle cells and M2 macrophages in atherosclerotic plaque, and its expression gradually decreases in the fibrous cap during the transition from stable to vulnerable atherosclerotic plaque. Valsartan, an AT1 receptor antagonist, promotes the stabilization of atherosclerotic plaque by increasing the levels of renalase in serum and the expression of renalase in the fibrous cap of atherosclerotic plaque. It also reduces triglyceride levels in serum and increases the expression of renalase in the liver. CONCLUSIONS:Renalase may be a potential-related gene of lipid metabolism and As, and it may be the possible molecular target of valsartan to help stabilize atherosclerotic plaque.

authors

Zhou M,Ma C,Liu W,Liu H,Wang N,Kang Q,Li P

doi

10.1177/1074248415575967

subject

Has Abstract

pub_date

2015-09-01 00:00:00

pages

509-19

issue

5

eissn

1074-2484

issn

1940-4034

pii

1074248415575967

journal_volume

20

pub_type

杂志文章
  • A Quarter of a Century Later: What is Dofetilide's Clinical Role Today?

    abstract::Dofetilide is a class III antiarrhythmic agent approved by the Food and Drug Administration for the conversion of atrial fibrillation and atrial flutter and maintenance of sinus rhythm in symptomatic patients with persistent arrhythmia. Drug trials showed neutral mortality in post-myocardial infarction patients and th...

    journal_title:Journal of cardiovascular pharmacology and therapeutics

    pub_type: 杂志文章,评审

    doi:10.1177/1074248418784288

    authors: Wolbrette DL,Hussain S,Maraj I,Naccarelli GV

    更新日期:2019-01-01 00:00:00

  • Comparison of the Electromechanical Effects of Vesnarinone and Amrinone in Isolated Dog Purkinje Strands and Ventricular Trabeculae.

    abstract::BACKGROUND: Conventional microelectrode techniques were used to compare the concentration-dependent effects of vesnarinone (0.1-100 µM) and amrinone (1 µM-1 mM) on action potential duration (APD) and developed force in both isolated dog ventricular trabeculae and Purkinje strands. METHODS AND RESULTS: Both drugs incre...

    journal_title:Journal of cardiovascular pharmacology and therapeutics

    pub_type: 杂志文章

    doi:10.1177/107424849600100207

    authors: Lathrop DA,Nánási PP,Varró A,Schwartz A

    更新日期:1996-04-01 00:00:00

  • Chronic treatment with qiliqiangxin ameliorates aortic endothelial cell dysfunction in diabetic rats.

    abstract::Qiliqiangxin (QL), a traditional Chinese medicine, has been shown to be beneficial for chronic heart failure. However, whether QL can also improve endothelial cell function in diabetic rats remains unknown. Here, we investigated the effect of QL treatment on endothelial dysfunction by comparing the effect of QL to tha...

    journal_title:Journal of cardiovascular pharmacology and therapeutics

    pub_type: 杂志文章

    doi:10.1177/1074248414537705

    authors: Chen F,Wu JL,Fu GS,Mou Y,Hu SJ

    更新日期:2015-03-01 00:00:00

  • Effects of rotigaptide, a gap junction modifier, on defibrillation energy and resuscitation from cardiac arrest in rabbits.

    abstract::The gap junction modifier Rotigaptide (ZP123), which promotes cellular coupling, was hypothesized to decrease defibrillation thresholds during prolonged ventricular fibrillation (VF). Thirty-two New Zealand white rabbits were randomized to receive saline (control, n = 16) or Rotigaptide (n = 16). Following 4 min of un...

    journal_title:Journal of cardiovascular pharmacology and therapeutics

    pub_type: 杂志文章

    doi:10.1177/1074248406298021

    authors: Zhong JQ,Laurent G,So PP,Hu X,Hennan JK,Dorian P

    更新日期:2007-03-01 00:00:00

  • Separate and combined effects of local and continuous intravenous administration of beta-cyclodextrin tetradecasulfate on intimal hyperplasia after angioplasty in porcine coronary arteries.

    abstract:BACKGROUND:Beta-Cyclodextrin tetradecasulfate binds fibroblast growth factors and possesses anticoagulant properties. This study was designed to assess the separate and combined effects of local intramural delivery and intravenous administration of beta-cyclodextrin tetrade-casulfate on neointimal formation and arteria...

    journal_title:Journal of cardiovascular pharmacology and therapeutics

    pub_type: 杂志文章

    doi:10.1177/107424840300800i108

    authors: Meneveau NF,Klugherz BD,Chaquor B,Golden MA,Jouille MM,Macarek E,Weisz PB,Wilensky RL

    更新日期:2003-03-01 00:00:00

  • Exploring the Quality of Anticoagulant Prescribed for Patients With Atrial Fibrillation at the St John of God Hawkesbury District Health Centre, New South Wales, Australia.

    abstract:BACKGROUND:Limited data are available on the clinical management of atrial fibrillation (AF) and its outcomes from an Australian perspective. OBJECTIVE:To describe the appropriateness of antithrombotic prescribing for patients who presented with a diagnosis of AF to the Hawkesbury St John of God Hospital, New South Wa...

    journal_title:Journal of cardiovascular pharmacology and therapeutics

    pub_type: 杂志文章

    doi:10.1177/1074248418786264

    authors: Wertheimer G,Bereznicki LR

    更新日期:2019-01-01 00:00:00

  • Circadian variation of stent thrombosis and the effect of more robust platelet inhibition: a post hoc analysis of the TRITON-TIMI 38 trial.

    abstract:BACKGROUND:The well-described morning peak in the onset of acute coronary syndromes has been partly attributed to increased platelet activity upon arising. It has been suggested that stent thrombosis (ST) exhibits a similar pattern. We assessed whether a diurnal variation in ST occurs, and whether more robust antiplate...

    journal_title:Journal of cardiovascular pharmacology and therapeutics

    pub_type: 杂志文章,随机对照试验

    doi:10.1177/1074248413497534

    authors: Mogabgab O,Wiviott SD,Cannon CP,Sloan S,Sabatine MS,Antman EM,Braunwald E,Giugliano RP

    更新日期:2013-11-01 00:00:00

  • Atorvastatin Pretreatment Inhibits Myocardial Inflammation and Apoptosis in Swine After Coronary Microembolization.

    abstract:BACKGROUND/AIM:In addition to its cholesterol-lowering effect, atorvastatin (ATV) has been thought to have multiple cardiovascular benefits, including anti-inflammatory and anti-apoptotic properties. The present study was undertaken to determine whether ATV pretreatment could attenuate myocardial apoptosis and inflamma...

    journal_title:Journal of cardiovascular pharmacology and therapeutics

    pub_type: 杂志文章

    doi:10.1177/1074248416662348

    authors: Wang JY,Chen H,Su X,Zhou Y,Li L

    更新日期:2017-03-01 00:00:00

  • Persistence of Atrial Fibrillation After Its Induction-Importance of the Duration and Dispersion of Atrial Refractoriness and Electrical Remodeling.

    abstract::BACKGROUND: The electrophysiologic mechanisms of the persistence of atrial fibrillation (AF) after its initiation are not well understood. Therefore, the electrophysiologic characteristics of the right atrium were evaluated in an acute, pacing-induced model of AF in the pig in order to identify parameters associated w...

    journal_title:Journal of cardiovascular pharmacology and therapeutics

    pub_type: 杂志文章

    doi:10.1177/107424849900400206

    authors: Rahme MM,Cotter B,Leistad E,Subudhayangkul S,Wadhwa M,Ungab G,Feld GK

    更新日期:1999-04-01 00:00:00

  • Comparing Diuresis Patterns in Hospitalized Patients With Heart Failure With Reduced Versus Preserved Ejection Fraction: A Retrospective Analysis.

    abstract:BACKGROUND:Congestion predominates in exacerbations of heart failure with reduced ejection fraction (HFrEF) or preserved ejection fraction (HFpEF), but evidence suggests that excess volume may be distributed differently in these 2 subgroups. METHODS AND RESULTS:In this retrospective study, diuretic efficiency (DE, or ...

    journal_title:Journal of cardiovascular pharmacology and therapeutics

    pub_type: 杂志文章

    doi:10.1177/1074248420960930

    authors: Broscious R,Kukin A,Noel ZR,Devabhakthuni S,Seung H,Ramani GV,Reed BN

    更新日期:2021-03-01 00:00:00

  • Relaxin' the Heart: A Novel Therapeutic Modality.

    abstract::The peptide hormone relaxin has traditionally been linked to the maternal adaptation of the cardiovascular system during the first trimester of pregnancy. By promoting nitric oxide formation through different molecular signaling events, relaxin has been proposed as a pleiotropic and cardioprotective hormone in the set...

    journal_title:Journal of cardiovascular pharmacology and therapeutics

    pub_type: 杂志文章,评审

    doi:10.1177/1074248415617851

    authors: Raleigh JM,Toldo S,Das A,Abbate A,Salloum FN

    更新日期:2016-07-01 00:00:00

  • Imipramine-induced cardiac depression is responsible for the increase in intracellular magnesium and the activation of ERK 1/2 in rats.

    abstract::Imipramine, an antidepressant drug, can cause potentially lethal cardiotoxic side effects including hypotension, ventricular tachycardia, and decreased cardiac output. This study investigated the mechanism responsible for imipramine-induced cardiac depression in rats. The left ventricular developed pressure (LVDP), ve...

    journal_title:Journal of cardiovascular pharmacology and therapeutics

    pub_type: 杂志文章

    doi:10.1177/1074248410366853

    authors: Lee MY,Kim SJ,Kim JS,Kang HS

    更新日期:2010-09-01 00:00:00

  • Cardioprotective Effects of Red Blood Cells on Ischemia and Reperfusion Injury in Isolated Rat Heart: Release of Nitric Oxide as a Potential Mechanism.

    abstract::BACKGROUND: Circulating cells influence myocardial function during ischemia and reperfusion, (eg, neutrophils exacerbate, and platelets protect the myocardium from deterioration). This study was designed to determine the role of red blood cells on myocardial function following ischemia and reperfusion in isolated rat ...

    journal_title:Journal of cardiovascular pharmacology and therapeutics

    pub_type: 杂志文章

    doi:10.1177/107424849600100405

    authors: Yang BC,Nichols WW,Mehta JL

    更新日期:1996-10-01 00:00:00

  • Effect of simvastatin/ezetimibe 10/10 mg versus simvastatin 40 mg on serum vitamin D levels.

    abstract:BACKGROUND:Low levels of 25-hydroxyvitamin D (25(OH)VitD) have been recognized as an emerging cardiovascular disease (CVD) risk factor. Statins are reported to increase 25(OH)VitD concentration. Animal studies suggest that ezetimibe is a moderate inhibitor of intestinal 25(OH)VitD absorption, but its effect in humans i...

    journal_title:Journal of cardiovascular pharmacology and therapeutics

    pub_type: 杂志文章,随机对照试验

    doi:10.1177/1074248412470513

    authors: Liberopoulos EN,Makariou SE,Moutzouri E,Kostapanos MS,Challa A,Elisaf M

    更新日期:2013-05-01 00:00:00

  • Omapatrilat induces profound renal vasodilation but does not affect coronary hemodynamics.

    abstract:BACKGROUND:Omapatrilat has potent enzymatic inhibitory effects on the angiotensin-converting enzyme and neutral endopeptidase. The prolonged effects of this inhibition on systemic and regional hemodynamics, cardiovascular mass, and hydroxyproline concentration in spontaneously hypertensive rats were studied. The contri...

    journal_title:Journal of cardiovascular pharmacology and therapeutics

    pub_type: 杂志文章

    doi:10.1177/107424840300800210

    authors: Varagic J,Susic D,Slama M,Frohlich ED

    更新日期:2003-06-01 00:00:00

  • Cardiovascular risk of selective cyclooxygenase-2 inhibitors.

    abstract::Recently, cyclooxygenase-2 (COX-2) inhibitors (coxibs), a class of drugs intended to be painkillers, have created unprecedented controversy because of their cardiovascular risk profile. The controversy has affected the patients, health-care providers, the Food and Drug Administration, and the manufacturers of these ag...

    journal_title:Journal of cardiovascular pharmacology and therapeutics

    pub_type: 杂志文章,评审

    doi:10.1177/107424840501000203

    authors: Schrör K,Mehta P,Mehta JL

    更新日期:2005-06-01 00:00:00

  • Sarcoplasmic reticulum adenosine triphosphatase overexpression in the L-type Ca2+ channel mouse results in cardiomyopathy and Ca2+ -induced arrhythmogenesis.

    abstract:BACKGROUND:Overexpression of the L-type voltage-dependent calcium channel alpha(1C)-subunit (L-VDCC OE) in transgenic mice results in adaptive hypertrophy followed by a maladaptive phase associated with a decrease in sarcoplasmic reticulum adenosine triphosphatase (SERCA)2a expression at 8 to 10 months of age. Overexpr...

    journal_title:Journal of cardiovascular pharmacology and therapeutics

    pub_type: 杂志文章

    doi:10.1177/107424840501000404

    authors: Rubio M,Bodi I,Fuller-Bicer GA,Hahn HS,Periasamy M,Schwartz A

    更新日期:2005-12-01 00:00:00

  • The cycloxygenase 2 (COX-2) story: it's time to explain, not inflame.

    abstract::Despite initial promising reports that anti-inflammatory properties of cycloxygenase-2 (COX-2) inhibitors may confer anti-atherosclerosis effects and stabilize the atherosclerotic plaque, subsequent data from long-term clinical trials have shown that selective COX-2 inhibitors are associated with increased risk of car...

    journal_title:Journal of cardiovascular pharmacology and therapeutics

    pub_type: 杂志文章,评审

    doi:10.1177/1074248407301172

    authors: Salinas G,Rangasetty UC,Uretsky BF,Birnbaum Y

    更新日期:2007-06-01 00:00:00

  • Chronic treatment with N-acetylcysteine improves cardiac function but does not prevent progression of cardiomyopathy in Syrian cardiomyopathic hamsters.

    abstract::Oxidative stress has been postulated to contribute to the onset and development of heart failure (HF). The efficacy of antioxidant therapy in HF, however, remains controversial. This study evaluates the effect of the antioxidant N-acetylcysteine (NAC, 1 g/kg per day) on cardiovascular function in 2- and 6-month-old Bi...

    journal_title:Journal of cardiovascular pharmacology and therapeutics

    pub_type: 杂志文章

    doi:10.1177/1074248410387281

    authors: Crespo MJ,Cruz N,Altieri PI,Escobales N

    更新日期:2011-06-01 00:00:00

  • Treatment Discontinuation or Interruption in Pulmonary Arterial Hypertension.

    abstract::Pulmonary arterial hypertension (PAH) is a progressive disease, which can be potentially fatal. The management of a complex disease like PAH requires a multidisciplinary approach from a team consisting of physicians, nurses, social workers, and pharmacists. Adherence to PAH-specific therapy is one of the key factors i...

    journal_title:Journal of cardiovascular pharmacology and therapeutics

    pub_type: 杂志文章,评审

    doi:10.1177/1074248419877409

    authors: Narechania S,Torbic H,Tonelli AR

    更新日期:2020-03-01 00:00:00

  • Cardioprotection induced by AT1R blockade after reperfused myocardial infarction: association with regional increase in AT2R, IP3R and PKCepsilon proteins and cGMP.

    abstract:BACKGROUND:We hypothesized that the cardioprotective effect of angiotensin II (AngII) type 1 receptor (AT(1)R) blockade during in vivo ischemia-reperfusion (IR) might be associated with an increase in AngII type 2 receptor (AT(2)R) protein, as well as 1,4,5-inositol trisphosphate type 2 receptor (IP(3)R) and protein ki...

    journal_title:Journal of cardiovascular pharmacology and therapeutics

    pub_type: 杂志文章

    doi:10.1054/JCPT.2000.19245

    authors: Jugdutt BI,Xu Y,Balghith M,Moudgil R,Menon V

    更新日期:2000-10-01 00:00:00

  • Curcumin attenuates cardiopulmonary bypass-induced lung oxidative damage in rats.

    abstract:OBJECTIVE:Acute lung injury is a common complication after cardiopulmonary bypass (CPB). Oxidative damage greatly impacts CPB-induced lung ischemic pathogenesis and may represent a target for treatment. We aimed to investigate whether curcumin upregulates heme oxygenase 1 (HO-1) expression and ameliorates lung injury i...

    journal_title:Journal of cardiovascular pharmacology and therapeutics

    pub_type: 杂志文章

    doi:10.1177/1074248412442002

    authors: Liu K,Chen HL,Huang H,Jing H,Dong GH,Wu HW,You QS

    更新日期:2012-12-01 00:00:00

  • MethotrexaTE THerapy in ST-Segment Elevation MYocardial InfarctionS: A Randomized Double-Blind, Placebo-Controlled Trial (TETHYS Trial).

    abstract:PURPOSE:Methotrexate is an anti-inflammatory drug that has been shown to have anti-ischemic effects. Our aim was to evaluate if methotrexate could reduce infarct size in patients with ST-segment elevation myocardial infarction (STEMI). METHODS:We randomly assigned patients with STEMI to receive either methotrexate or ...

    journal_title:Journal of cardiovascular pharmacology and therapeutics

    pub_type: 杂志文章,随机对照试验

    doi:10.1177/1074248417699884

    authors: Moreira DM,Lueneberg ME,da Silva RL,Fattah T,Gottschall CAM

    更新日期:2017-11-01 00:00:00

  • Hypothesis: atorvastatin has pleiotropic effects that translate into early clinical benefits on cardiovascular disease.

    abstract::The results of numerous long-term, randomized trials show that statins significantly decrease the risks of myocardial infarction, stroke, and vascular death as well as total mortality. The benefits of statins on cardiovascular disease in patients who are not experiencing acute coronary syndromes generally become appar...

    journal_title:Journal of cardiovascular pharmacology and therapeutics

    pub_type: 杂志文章,评审

    doi:10.1177/107424840400900i109

    authors: Novela C,Hennekens CH

    更新日期:2004-03-01 00:00:00

  • Ischemic Conditioning Attenuates Platelet-Mediated Thrombosis: A Tale of Reverse Translation.

    abstract::Data obtained in both preclinical models and humans have revealed that the favorable cardiac consequences of ischemic conditioning extend beyond a direct effect on the cardiomyocyte. In the current review, we summarize our as-yet limited understanding of the complex relationships between ischemic conditioning, platele...

    journal_title:Journal of cardiovascular pharmacology and therapeutics

    pub_type: 杂志文章,评审

    doi:10.1177/1074248417724871

    authors: Przyklenk K,Whittaker P

    更新日期:2017-09-01 00:00:00

  • Sinus node dysfunction secondary to hyperparathyroidism.

    abstract::We present two patients who were diagnosed with symptomatic sinus node dysfunction in the setting of hypercalcemia secondary to hyperparathyroidism. An extensive review of the literature has not revealed previous reports of this pathologic process. ...

    journal_title:Journal of cardiovascular pharmacology and therapeutics

    pub_type: 杂志文章

    doi:10.1177/107424840400900209

    authors: Shah AP,Lopez A,Wachsner RY,Meymandi SK,El-Bialy AK,Ichiuji AM

    更新日期:2004-06-01 00:00:00

  • Ischemic Conditioning in Kidney Transplantation.

    abstract::Ischemia-reperfusion injury is a composite of the injury sustained during a period of reduced or absent blood flow to a tissue or organ and the additional insult sustained on reperfusion, which limits the amount of tissue that can be salvaged. Ischemia-reperfusion injury is the predominant insult during kidney transpl...

    journal_title:Journal of cardiovascular pharmacology and therapeutics

    pub_type: 杂志文章,评审

    doi:10.1177/1074248417702893

    authors: Veighey K,MacAllister R

    更新日期:2017-07-01 00:00:00

  • Review article: the new concept of interventional heart failure therapy--part 1: electrical therapy, treatment of CAD, fluid removal, and ventricular support.

    abstract::Congestive heart failure is a chronic and debilitating disease responsible for high cardiac morbidity and mortality in the world and is associated with more than 290 000 deaths in the United States each year. Recent advances in heart failure therapy target many of the mechanical and structural aspects of heart failure...

    journal_title:Journal of cardiovascular pharmacology and therapeutics

    pub_type: 杂志文章,评审

    doi:10.1177/1074248410366447

    authors: Thompson KA,Philip KJ,Barbagelata A,Schwarz ER

    更新日期:2010-06-01 00:00:00

  • CMX-2043 Efficacy in a Rat Model of Cardiac Ischemia-Reperfusion Injury.

    abstract::α-Lipoic acid (LA) has been shown to offer protection against ischemia-reperfusion injury (IRI) in multiple organ systems. N-[(R)-1,2-dithiolane-3-pentanoyl]-L-glutamyl-L-alanine (CMX-2043), a novel analogue of LA, was studied as part of a preclinical development program intended to identify safe and efficacious drug ...

    journal_title:Journal of cardiovascular pharmacology and therapeutics

    pub_type: 杂志文章

    doi:10.1177/1074248416640118

    authors: Baguisi A,Casale RA,Kates SA,Lader AS,Stewart K,Beeuwkes R 3rd

    更新日期:2016-11-01 00:00:00

  • Variations in plasma free radicals in patients with venous hypertension with HR (Paroven, Venoruton; 0-(beta-hydroxyethyl)-rutosides): a clinical, prospective, placebo-controlled, randomized trial.

    abstract::The aim of this study was to demonstrate whether HR (Paroven, Venoruton; 0-(beta-hydroxyethyl)-rutosides), was effective in improving levels of plasma free radicals (PFRs) in patients with chronic venous insufficiency (CVI) and venous microangiopathy. Patients were randomized into the treatment group, which received o...

    journal_title:Journal of cardiovascular pharmacology and therapeutics

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1177/107424840200700107

    authors: Cesarone MR,Incandela L,DeSanctis MT,Belcaro G,Dugall M,Acerbi G

    更新日期:2002-01-01 00:00:00